← Back to Home

Efficacy Durability Falls Short and Deaths Occur in Trials as Artiva Discontinues AlloNK and Cuts 94% of Its Workforce

An autoimmune cell therapy previously slated to advance into Phase 3 has taken an abrupt turn. With two deaths attributed to different causes and insufficient long-term efficacy, Artiva has decided to halt development and evaluate a merger, asset sales or liquidation.

By SURL BioNews

Whether cell therapies can transform the treatment of autoimmune diseases depends not only on initial symptom improvement, but also on how long the effects last and how much risk patients must bear. On October 27, Artiva Biotherapeutics announced that it would discontinue development of AlloNK (AB-101), cancel its planned Phase 3 trial and reduce its workforce by approximately 94%. The decision followed long-term efficacy that fell short of the company’s expectations and two successive deaths in clinical trials.

AlloNK is a non-genetically modified, cryopreservable allogeneic natural killer (NK) cell therapy being developed in combination with the B-cell-targeting antibody rituximab to treat autoimmune diseases such as rheumatoid arthritis. As recently as September this year, Artiva was still planning to advance a Phase 3 trial in refractory rheumatoid arthritis while awaiting at least six months of follow-up for more patients.

With extended follow-up, however, the early signals failed to support further investment. The company said updated data continued to show deep B-cell depletion and clinical activity consistent with earlier findings, but the durability of efficacy did not meet the threshold required to continue development. After assessing the benefits and risks, potential enrollment delays, and development and commercial prospects, Artiva decided to halt the program. The announcement did not provide complete data sufficient to quantify the shortfall in durability.

On safety, a participant in a Phase 2a basket trial developed fatal leukoencephalopathy after receiving treatment. The treatment regimen included lymphodepleting preconditioning with cyclophosphamide and fludarabine. According to the company’s announcement, both the investigator and an independent safety review judged the event highly likely to be related to fludarabine-associated neurotoxicity. After being notified, the U.S. Food and Drug Administration (FDA) required enrollment and dosing in that trial to be paused.

Another participant died suddenly approximately two months after starting treatment, with the cause of death yet to be determined. The investigator assessed the death as unrelated to AlloNK or any other component of the trial regimen. The attribution of the two events therefore needs to be understood separately: the information currently available is insufficient to attribute both deaths to the NK-cell product, and it also cannot rule out risks associated with the overall regimen that require further clarification.

With development discontinued, no patients in any ongoing AlloNK clinical studies will receive further dosing, and the planned pivotal Phase 3 trial will not begin. The company will coordinate with the FDA, investigators and institutional review boards to close the studies, while continuing necessary safety follow-up and reporting.

As it winds down the clinical program, Artiva will also substantially reduce its organization and has engaged Leerink Partners to evaluate options including a merger, asset sales or licensing, and dissolution and liquidation. No transaction has been finalized, and the company said the strategic review does not guarantee any particular outcome.

This turn of events illustrates a challenge in developing cell therapies for autoimmune diseases: B-cell depletion and initial improvement still require long-term follow-up to determine whether they are sufficient to justify the risks and burdens of the entire treatment regimen. Artiva plans to share more details of the first death through a scientific publication. Until complete efficacy data and case analyses are made public, there remain limits to how much the program’s results can inform other cell therapies.

References

  1. Fierce Biotech
  2. Artiva Biotherapeutics via GlobeNewswire, republished by Stock Titan